The untold story of the beginning of the coronavirus pandemic and how China responded. Chinese scientists and doctors, international disease experts and health officials reveal missed opportunities to suppress the outbreak and lessons for the world.
WHO should continue to provide all necessary technical and operational support to respond to this outbreak, including with its extensive networks of partners and collaborating institutions, to implement a comprehensive risk communication strategy, and to allow for the advancement of research and scientific developments in relation to this novel coronavirus.
Pew Research Center conducted these surveys to understand how Americans think about privacy, data collection, surveillance and smartphone tracking, including in the context of the new coronavirus outbreak.
The COVID-19 pandemic, also known as the coronavirus pandemic, is an ongoing global pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The novel virus was first identified in an outbreak in the Chinese city of Wuhan in December 2019. Attempts to contain it there failed, allowing the virus to spread to other areas of Asia and later worldwide. The World Health Organization (WHO) declared the outbreak a public health emergency of international concern on 30 January 2020, and a pandemic on 11 March 2020. As of 10 March 2023, the pandemic had caused more than 676 million cases and 6.88 million confirmed deaths, making it one of the deadliest in history.
The pandemic is known by several names. It is sometimes referred to as the \"coronavirus pandemic\" despite the existence of other human coronaviruses that have caused epidemics and outbreaks (e.g. SARS).
During the initial outbreak in Wuhan, the virus and disease were commonly referred to as \"coronavirus\", \"Wuhan coronavirus\", \"the coronavirus outbreak\" and the \"Wuhan coronavirus outbreak\", with the disease sometimes called \"Wuhan pneumonia\". In January 2020, the WHO recommended 2019-nCoV and 2019-nCoV acute respiratory disease as interim names for the virus and disease per 2015 international guidelines against using geographical locations (e.g. Wuhan, China), animal species, or groups of people in disease and virus names in part to prevent social stigma. WHO finalized the official names COVID-19 and SARS-CoV-2 on 11 February 2020. Tedros Adhanom Ghebreyesus explained: CO for corona, VI for virus, D for disease and 19 for when the outbreak was first identified (31 December 2019). WHO additionally uses \"the COVID-19 virus\" and \"the virus responsible for COVID-19\" in public communications.
SARS-CoV-2 is a virus closely related to bat coronaviruses, pangolin coronaviruses, and SARS-CoV. The first known outbreak (the 2019-2020 COVID-19 outbreak in mainland China) started in Wuhan, Hubei, China, in November 2019. Many early cases were linked to people who had visited the Huanan Seafood Wholesale Market there, but it is possible that human-to-human transmission began earlier.
On 11 January, WHO was notified by the Chinese National Health Commission that the outbreak was associated with exposures in the market, and that China had identified a new type of coronavirus, which it isolated on 7 January.
Video footage from Wuhan during the earliest days of the COVID-19 outbreak shows how the Chinese government could have done more to prevent the coronavirus from spreading, and its attempts to stop journalists from reporting on it.
The charges are the latest in a series of aggressive Trump administration actions targeting China. It comes as President Donald Trump, his reelection prospects damaged by the coronavirus outbreak, has blamed China for the pandemic.
We describe the results of testing health care workers, from a tertiary care hospital in Japan that had experienced a coronavirus disease 2019 (COVID-19) outbreak during the first peak of the pandemic, for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibody seroconversion. Using two chemiluminescent immunoassays and a confirmatory surrogate virus neutralization test, serological testing revealed that a surprising 42% of overlooked COVID-19 diagnoses (27/64 cases) occurred when case detection relied solely on SARS-CoV-2 nucleic acid amplification testing (NAAT). Our results suggest that the NAAT-positive population is only the tip of the iceberg and the portion left undetected might potentially have led to silent transmissions and triggered the spread. A questionnaire-based risk assessment was further indicative of exposures to specific aerosol-generating procedures (i.e., noninvasive ventilation and airway suctioning) having mediated transmission and served as the origins of the outbreak. Our observations are supportive of a multitiered testing approach, including the use of serological diagnostics, in order to accomplish exhaustive case detection along the whole COVID-19 spectrum. IMPORTANCE We describe the results of testing frontline health care workers, from a hospital in Japan that had experienced a COVID-19 outbreak, for SARS-CoV-2-specific antibodies. Antibody testing revealed that a surprising 42% of overlooked COVID-19 diagnoses occurred when case detection relied solely on PCR-based viral detection. COVID-19 clusters have been continuously striking the health care system around the globe. Our findings illustrate that such clusters are lined with hidden infections eluding detection with diagnostic PCR and that the cluster burden in total is more immense than actually recognized. The mainstays of diagnosing infectious diseases, including COVID-19, generally consist of two approaches, one aiming to detect molecular fragments of the invading pathogen and the other to measure immune responses of the host. Considering antibody testing as one trustworthy option to test our way through the pandemic can aid in the exhaustive case detection of COVID-19 patients with variable presentations.
Earlier this spring, the Secret Service dealt with a similar, albeit significantly less widespread, outbreak of coronavirus among its ranks. And shortly after the president's hospitalization in October, agents reportedly began complaining that the Trump's campaign's seeming laxness regarding COVID-19 protections was becoming an occupational hazard.
The coronavirus seems to be exerting itself upon all phases of life, and your intellectual property is not immune. While you, your families, your friends, and your colleagues are getting comfortable with the new normal of social-distancing, intellectual property (IP) offices worldwide have also been grappling with how to handle the impact of coronavirus (also referred to as COVID-19). Responses from IP offices around the world are varied and evolving, as the landscape changes in each individual country and on a global scale. For example, some offices, such as the European Patent Office (EPO), India, and the United Kingdom, have automatically extended deadlines, while others have refrained from any extensions but permit, under certain circumstances, remedial action for rights lost due to effects of the coronavirus. While the U.S. Patent and Trademark Office (USPTO) has not provided for automatic extensions, certain deadlines associated with patent and trademark filings and fees may be extended for small and micro entities provided the delay in filing or payment was due to the COVID-19 outbreak. Additionally, the USPTO will waive the petition fee to revive certain lost rights resulting from a failure to take action due to effects of the coronavirus.
Several ships owned by Carnival were hit by outbreaks of COVID-19 that left more than a dozen dead and hundreds of others sick. The company and its subsidiary lines are the subject of numerous lawsuits filed by passengers who were exposed to the coronavirus. 59ce067264